185 related articles for article (PubMed ID: 35969350)
1. A m
Lei M; Luo C; Zhang J; Cao W; Ge J; Zhao M
Cell Oncol (Dordr); 2022 Oct; 45(5):931-949. PubMed ID: 35969350
[TBL] [Abstract][Full Text] [Related]
2. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
3. LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response.
Huang J; Yuan L; Huang W; Liao L; Zhu X; Wang X; Li J; Liang W; Wu Y; Liu X; Yu D; Zheng Y; Guan J; Zhan Y; Liu L
Front Immunol; 2022; 13():1064874. PubMed ID: 36505456
[TBL] [Abstract][Full Text] [Related]
4. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
6. An immune indicator based on BTK and DPEP2 identifies hot and cold tumors and clinical treatment outcomes in lung adenocarcinoma.
Han T; Liu Y; Wu J; Bai Y; Zhou J; Hu C; Zhang W; Guo J; Wang Q; Hu D
Sci Rep; 2023 Mar; 13(1):5153. PubMed ID: 36991102
[TBL] [Abstract][Full Text] [Related]
7. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
[TBL] [Abstract][Full Text] [Related]
8. Validating a Macrophage Marker Gene Signature (MMGS) in Lung Adenocarcinoma Prognosis and Response to Immunotherapy.
Song P; Wusiman D; Li W; Guo L; Ying J; Gao S; He J
J Immunother; 2023 Jul-Aug 01; 46(6):205-215. PubMed ID: 37220007
[TBL] [Abstract][Full Text] [Related]
9. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
[TBL] [Abstract][Full Text] [Related]
10. A novel zinc metabolism-related gene signature to predict prognosis and immunotherapy response in lung adenocarcinoma.
Chang W; Li H; Ou W; Wang SY
Front Immunol; 2023; 14():1147528. PubMed ID: 37033934
[TBL] [Abstract][Full Text] [Related]
11. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
12.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
13. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
14. The integrated single-cell analysis developed a lactate metabolism-driven signature to improve outcomes and immunotherapy in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Ren Q; Xie J; Liu H; Wang W
Front Endocrinol (Lausanne); 2023; 14():1154410. PubMed ID: 37033259
[TBL] [Abstract][Full Text] [Related]
15. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
16. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
17. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma.
Zhang P; Pei S; Gong Z; Feng Y; Zhang X; Yang F; Wang W
Front Immunol; 2023; 14():1115272. PubMed ID: 36776843
[TBL] [Abstract][Full Text] [Related]
18. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
19. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
Li Z; Guo M; Lin W; Huang P
Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
[TBL] [Abstract][Full Text] [Related]
20. Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma.
Zhang L; Wu J; Yin WW; Hu J; Liao L; Ma J; Xu Z; Wu S
Pathol Res Pract; 2024 Jan; 253():155048. PubMed ID: 38147724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
